Vol 69, No 1 (2018)
Original article
Published online: 2018-03-28

open access

Page views 1974
Article views/downloads 1397
Get Citation

Connect on Social Media

Connect on Social Media

Benzodiazepine prescriptions on merchant ships without a doctor on board: analysis from medical records of Centro Internazionale Radio Medico (CIRM)

Giulio Nittari1, Graziano Pallotta1, Marzio Di Canio2, Enea Traini1, Francesco Amenta12
Pubmed: 29611611
IMH 2018;69(1):28-34.

Abstract

Background: Benzodiazepines are drugs widely used for the treatment of anxiety and insomnia. The present study has analysed the prescriptions of this class of drugs among sailing seafarers, to evaluate the appropriateness of prescribed therapies.

Materials and methods: This study assessed the benzodiazepine prescriptions made by Centro Internazionale Radio Medico (CIRM) doctors from 2011 to 2015. A total of 17,844 medical records were examined. Analysis considered the prescriptions of benzodiazepines in monotherapy, or in association with other drugs. Diagnoses of pathologies for which benzodiazepines were prescribed were made according to the ICD-10 classification system proposed by the World Health Organisation.

Results: Among medical records analysed, benzodiazepines were prescribed in 765 cases (3.29% of total cases assisted by CIRM). Benzodiazepines were prescribed as a single-drug treatment in 626 (81.83%) cases, whereas in 139 cases they were associated with other classes of drugs. In case of opioids prescribed in association with benzodiazepines, the drug used was codeine. This therapeutic association was prescribed in cases of severe pain.

Conclusions: Although the “off label” use of benzodiazepines is not uncommon in medical practice, clear evidence indicates their potential side effects for human health. In this respect, medical professionals should comply with international guidelines on the use of benzodiazepines, both when prescribed as a single drug or in combination with other classes of drugs. These recommendations should be considered seriously in case of limited medical facilities such as on board of sailing ships.  

Article available in PDF format

View PDF Download PDF file

References

  1. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev. 1992; 44(2): 151–347.
  2. Martin JL, Sainz-Pardo M, Furukawa TA, et al. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007; 21(7): 774–782.
  3. Balkom AJ, Bakker A, Spinhoven P, et al. A Meta-Analysis of the Treatment of Panic Disorder with or without Agoraphobia: A Comparison of Psychopharmacological, Cognitive-Behavioral, and Combination Treatments. J Nerv Ment Dis. 1997; 185(8): 510–516.
  4. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007; 22(9): 1335–1350.
  5. Rickels K, Schweizer E, Case WG, et al. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990; 47(10): 899–907.
  6. Fenton MC, Keyes KM, Martins SS, et al. The role of a prescription in anxiety medication use, abuse, and dependence. Am J Psychiatry. 2010; 167(10): 1247–1253.
  7. American Psychiatric Association Task Force on Benzodiazepine Dependency. Benzodiazepine Dependence, Toxicity, and Abuse. American Psychiatric Publishing, Arlington 1990.
  8. Abernethy DR, Greenblatt DJ, Steel K, et al. Impairment of hepatic drug oxidation by propoxyphene. Ann Intern Med. 1982; 97(2): 223–224.
  9. Product Information: OxyContin(R) oral controlled-release tablets, oxycodone HCl oral controlled-release tablets. Purdue Pharma L.P. (for FDA), Stamford, CT, Apr, 2013.
  10. U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 1-888-INFO-FDA(1-888-4636332). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697.htm.
  11. Mahdi SS, Amenta F. Eighty years of CIRM. A journey of commitment and dedication in providing maritime medical assistance. Int Marit Health. 2016; 67(4): 187–195.
  12. Ricci G, Cannovo N. The importance of the training of Ethics Committee members. Med Law. 2009; 28(4): 649–659.
  13. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009; 169(21): 1952–1960.
  14. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med. 2004; 164(14): 1567–1572.
  15. Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf. 2009; 18(7): 572–578.
  16. Cascade E, Kalali AH. Use of benzodiazepines in the treatment of anxiety. Psychiatry (Edgmont). 2008; 5(9): 21–22.
  17. Hogan DB, Maxwell CJ, Fung TS, et al. Canadian Study of Health and Aging. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. Can J Clin Pharmacol. 2003; 10(2): 72–77.
  18. Petitjean S, Ladewig D, Meier CR, et al. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol. 2007; 22(5): 292–298.
  19. Bolton JM, Metge C, Lix L, et al. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008; 28(4): 384–391.
  20. Simon GE, Ludman EJ. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen Hosp Psychiatry. 2006; 28(5): 374–378.
  21. Manthey L, Giltay EJ, van Veen T, et al. Determinants of initiated and continued benzodiazepine use in the Netherlands study of depression and anxiety. J Clin Psychopharmacol. 2011; 31(6): 774–779.
  22. Luijendijk HJ, Tiemeier H, Hofman A, et al. Determinants of chronic benzodiazepine use in the elderly: a longitudinal study. Br J Clin Pharmacol. 2008; 65(4): 593–599.
  23. Jorm AF, Grayson D, Creasey H, et al. Long-term benzodiazepine use by elderly people living in the community. Aust N Z J Public Health. 2000; 24(1): 7–10.
  24. Fourrier A, Letenneur L, Dartigues JF, et al. Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol. 2001; 57(5): 419–425.
  25. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003; 289(9): 1107–1116.
  26. National Institute for Clinical Excellence. Guidance on the Use of Zaleplon, Zolpidem and Zopiclone for the Short-term Management of Insomnia, Technology Appraisal 77. London, England: NICE; 2004. London, 2004.
  27. Goethe WHG, Watson EN, Jones DT. Handbook of Nautical Medicine. Springer-Verlag, Berlin 1984.
  28. International Maritime Organization: Medical Assistance at sea. MSC/Circ.960 Ref. T1/3.02 London SE1 7SR 20 June 2000.
  29. Ricci G, Pirillo I, Rinuncini C, et al. Medical assistance at the sea: legal and medico-legal problems. Int Marit Health. 2014; 65(4): 205–209.
  30. Ricci G, Pirillo I, Amenta F. Ethical challenges to medical assistance at sea. Marine Policy. 2017; 81: 247–249.
  31. Cook JM, Biyanova T, Masci C, et al. Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study. J Gen Intern Med. 2007; 22(8): 1094–1100.
  32. Bursztajn HJ, Brodsky A. Ethical and legal dimensions of benzodiazepine prescription: a commentary. Psychiatr Ann. 1998; 28(3): 121–127.
  33. Paul SM. Anxiety and depression: A common neurological substrate? J Clin Phychiatry. 1988; 49(suppl): 13–16.
  34. French JF, Rapoport RM, Matlib MA. Possible mechanism of benzodiazepine-induced relaxation of vascular smooth muscle. J Cardiovasc Pharmacol. 1989; 14(3): 405–411.
  35. Gifford RW. Management of hypertensive crises. JAMA. 1991; 266(6): 829–835.
  36. Chou R, Huffman LH. American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007; 147(7): 505–514.